Carlos AndrÃ©s RodrÃ-guez

List of Publications by Year
in descending order

30	628	759233 12	580821 25
papers	citations	h-index	g-index

34	34	34	739
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infectious Diseases, 2006, 6, 55.	2.9	149
2	Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator. Antimicrobial Agents and Chemotherapy, 2010, 54, 3271-3279.	3.2	88
3	Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clinical Pharmacology, 2009, 9, 1.	2.5	73
4	Determination of Therapeutic Equivalence of Generic Products of Gentamicin in the Neutropenic Mouse Thigh Infection Model. PLoS ONE, 2010, 5, e10744.	2.5	42
5	In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infectious Diseases, 2010, 10, 153.	2.9	35
6	Generic Vancomycin Enriches Resistant Subpopulations of Staphylococcus aureus after Exposure in a Neutropenic Mouse Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 243-247.	3.2	32
7	Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. Journal of Infection, 2009, 59, 277-280.	3.3	29
8	Even Apparently Insignificant Chemical Deviations among Bioequivalent Generic Antibiotics Can Lead to Therapeutic Nonequivalence: the Case of Meropenem. Antimicrobial Agents and Chemotherapy, 2014, 58, 1005-1018.	3.2	23
9	Optimization of culture conditions to obtain maximal growth of penicillin-resistant Streptococcus pneumoniae. BMC Microbiology, 2005, 5, 34.	3.3	19
10	In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products. International Journal of Antimicrobial Agents, 2017, 49, 189-197.	2.5	16
11	Impact on Resistance of the Use of Therapeutically Equivalent Generics: the Case of Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2015, 59, 53-58.	3.2	14
12	Perspectives for the structure-based design of acetylcholinesterase reactivators. Journal of Molecular Graphics and Modelling, 2016, 68, 176-183.	2.4	14
13	Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam. PLoS ONE, 2016, 11, e0155806.	2.5	11
14	About the Validation of Animal Models to Study the Pharmacodynamics of Generic Antimicrobials. Clinical Infectious Diseases, 2014, 59, 459-461.	5.8	10
15	Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam. International Journal of Antimicrobial Agents, 2015, 45, 161-167.	2.5	9
16	An Optimized Mouse Thigh Infection Model for Enterococci and Its Impact on Antimicrobial Pharmacodynamics. Antimicrobial Agents and Chemotherapy, 2015, 59, 233-238.	3.2	9
17	Staphylococcus aureus resistente a vancomicina.. Biomedica, 2005, 25, 575.	0.7	8
18	Population Pharmacokinetic Models of Antituberculosis Drugs in Patients: A Systematic Critical Review. Therapeutic Drug Monitoring, 2021, 43, 108-115.	2.0	7

#	Article	IF	Citations
19	Antifungal pharmacodynamics: Latin America's perspective. Brazilian Journal of Infectious Diseases, 2017, 21, 79-87.	0.6	6
20	A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone. PLoS ONE, 2020, 15, e0243365.	2.5	6
21	Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis. Therapeutic Drug Monitoring, 2019, 41, 719-725.	2.0	4
22	A strain-independent method to induce progressive and lethal pneumococcal pneumonia in neutropenic mice. Journal of Biomedical Science, 2015, 22, 24.	7.0	3
23	CIEMTO: the new drug and poison research and information center in MedellÃn, Colombia. Clinical Toxicology, 2017, 55, 684-685.	1.9	3
24	Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin. PLoS ONE, 2019, 14, e0211096.	2.5	3
25	Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model. BMC Research Notes, 2015, 8, 546.	1.4	2
26	Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis. PLoS ONE, 2015, 10, e0141872.	2.5	2
27	Title is missing!. , 2020, 15, e0243365.		0
28	Title is missing!. , 2020, 15, e0243365.		0
29	Title is missing!. , 2020, 15, e0243365.		0
30	Title is missing!. , 2020, 15, e0243365.		0